The disappointing oral AOD-9604 results do not establish that injections work better. A different route can create a new hypothesis, but it needs direct evidence rather than being used to explain away an unfavorable trial.
Identify the routes actually studied
The historical clinical-program report describes oral and intravenous investigations. These should not be relabeled as a program proving subcutaneous treatment.
The FDA's assessment specifically identified missing human evidence for the proposed subcutaneous and transdermal uses. Its route-related limitations are important when a website borrows the human-study record to promote another preparation.
Delivery and clinical benefit are not interchangeable
A claim that one route bypasses digestion does not establish a favorable clinical outcome. Researchers still need to characterize exposure, formulation, efficacy and harms for the intended use.
More exposure is not automatically better, and a smaller stated amount is not automatically safer. Those judgments depend on the intervention and clinical data, not just a general idea about how peptides behave.
The identity of the finished product matters too. A trial preparation and a research powder may share a name without demonstrated comparability.
Ask for an actual route comparison
A useful comparison would test defined preparations in comparable participants, using meaningful outcomes and systematic adverse-event collection. Reports from different forum users do not supply that design.
A person noticing a change after switching routes cannot isolate the cause if other factors also changed. A lack of response does not prove that the original route was the only problem.
For a prescribed treatment, discuss product and route questions with the responsible clinician and pharmacist. For research-only AOD-9604, this article supplies no injection method, oral amount or conversion.
The evidence-supported answer is limited: oral research exists, but it does not validate an injected workaround or establish which research-vial route a person should use.